Piper Sandler initiated coverage on Inventiva SA (NASDAQ:IVA), currently valued at $730 million, with an Overweight rating and a $26.00 price target on Wednesday. The stock has shown impressive momentum, gaining over 88% in the past year and trading near its 52-week high of $4.79.
The research firm highlighted Inventiva’s lead asset, lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), with Phase 3 NATiV3 topline results expected in the second half of 2026.
Piper Sandler noted that Inventiva’s current market capitalization of approximately $650 million represents a 14-times valuation gap compared to competitor Madrigal Pharmaceuticals’ $9.2 billion valuation in the MASH treatment space.
The firm specifically pointed to lanifibranor’s potential positioning for type 2 diabetes MASH patients, citing its benefits for glycemic control and insulin resistance, with an estimated 10.6 million F2-3 US MASH patients by 2030, approximately 15-20% of whom have type 2 diabetes comorbidity.
Piper Sandler views the upcoming Phase 3 NATiV3 trial results as a de-risked and potentially significant stock-moving event that could highlight lanifibranor’s value proposition in the MASH treatment landscape.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.